LONDON — The fear is familiar to almost any cardiologist. A patient with elevated cholesterol or a recent cardiac event gets a statin prescription and, weeks later, calls to say they have stopped taking it. Muscle pain, they explain. Or the possibility of it. Something they read online, something a neighbor mentioned. For the tens of millions of people who might benefit from statins but have never started, or started and stopped, a large study from the University of Oxford offers a direct answer to that fear.
Serious muscle disorders, specifically the kind requiring hospitalization or in rare cases proving fatal, affect fewer than two in every hundred people eligible for statin therapy over a ten-year period, according to ScienceDaily. The finding, built from the medical records of 5.6 million patients across England’s general practices, is among the most comprehensive examinations of statin-related muscle risk ever conducted.
The study also introduces a clinical tool designed to put those numbers to use. The STRATIFY-StatinMD calculator takes 22 individual health factors into account, including age, underlying conditions, and existing medications, and produces a patient-specific estimate of serious muscle disorder risk over one, five, or ten years. The goal is to move the conversation in doctors’ offices away from population averages and toward individual patients.
“Serious muscle disorders are one of the most widely discussed concerns about statins, but our findings suggest that the risk is very low,” said Dr. Ting Cai, the study’s lead author and a researcher at Oxford’s Nuffield Department of Primary Care Health Sciences. What the calculator offers, the research team argues, is a way to distinguish the minority of patients who face genuinely elevated risk from the majority who do not.
The distinction matters because statins remain one of the most underused medications in cardiovascular care. More than 60 percent of people who meet clinical criteria for statin therapy are not currently taking the drugs, the research team found. The gap between who qualifies and who actually fills a prescription is, in part, a fear gap, and the fear, the study suggests, may not be calibrated to the real risk.
What the calculator does not address is the range of milder muscle complaints that patients commonly report: aching, weakness, soreness that does not require a hospital visit. Those symptoms are real, and they drive much of the hesitation. STRATIFY-StatinMD was built specifically to predict serious muscle disorders, defined as conditions severe enough to require hospitalization or that contribute to death. Minor aches fall outside its scope.
The dataset behind the tool is large enough to give the findings statistical weight. Researchers used the records of 1.7 million patients to develop the calculator and tested its accuracy against a separate population of 3.9 million patients, all drawn from England’s network of general practice databases. The scale matters: earlier attempts to quantify statin muscle risk have often relied on clinical trials where patients are more carefully selected than in general practice, potentially underrepresenting people who might actually experience side effects.
Professor James Sheppard, a Professor of Primary Care Research at Oxford who contributed to the study, and Professor Constantinos Koshiaris of the University of Nicosia Medical School were among the collaborators. Their work builds on a growing body of research examining the gap between perceived and actual statin risk, including a June analysis finding that statin side effect warnings may not reflect drug-caused harm in most patients, and an April review of updated cholesterol guidelines that pushed recommended treatment to begin as early as a patient’s thirties.
The STRATIFY-StatinMD study was conducted in England, which limits its immediate applicability elsewhere. General practice patterns, prescription habits, and patient demographics vary between countries, and the risk factors incorporated into the calculator reflect the English population’s clinical characteristics. Whether the tool’s predictive accuracy holds in the United States, South Asia, or other major statin markets remains to be tested.
Within England, however, the research team believes the tool is ready for clinical use. The calculator is designed to be integrated into electronic health records, allowing it to flag elevated-risk patients automatically at the point of prescribing. In that framing, STRATIFY-StatinMD functions less as a patient-facing app than as a clinical decision-support tool, one that could help doctors identify the roughly two percent of eligible patients who face a meaningfully higher risk of serious muscle injury and treat them differently.
For the broader population of statin-hesitant patients, the study adds evidence to what cardiologists have argued for years: that the muscle side effects most people fear are common in the population generally and not uniquely caused by statins, and that serious muscle injury from statin use is rare. What it adds that earlier research did not is an individual-level estimate, a number attached to a specific patient rather than a population average, which is precisely what hesitant patients often ask for and rarely receive.
The study’s publication arrives as public health messaging around cardiovascular medication adherence has intensified. The CDC has tracked cardiovascular disease as the leading cause of death in the United States for decades, and treatment gaps in statin uptake are considered a significant contributor to preventable cardiac events. Whether a risk calculator developed from English medical records will move that needle in any jurisdiction remains an open question.
What the Oxford team has documented is that, for most patients, the serious risk is smaller than the conversation around statins has long suggested. The calculator gives doctors a way to say so with a number behind it.
